Current Status on Drug Delivery for Bone Tissue Engineering

Anushka Singh[1], Ashrita Srivalli Padmasolala[2], Prakash P[3], V. Ramesh Kumar[4], Manjunath[5]
[1,2,3,4,5]*Department of Biotechnology, Sathyabama Institute of Science and Technology, Chennai – 600119*



Abstract*—Bone tissue engineering (BTE) is focused on developing biological substitutes to repair critical bone defects that cannot heal on their own. An emerging strategy in BTE is to incorporate drug delivery systems into scaffolds to enhance regeneration. This review summarizes current approaches for delivering osteogenic signals (drugs, growth factors, genes) in BTE, highlighting their status, challenges, and future directions. Conventional systemic therapies (e.g. oral or injectable drugs) often suffer from poor bone targeting and side effects, motivating localized delivery strategies. Local controlled-release systems (scaffolds, nanoparticles, hydrogels) can provide sustained, site-specific delivery of bioactive molecules to promote bone healing while minimizing off-target effects. We discuss scaffold-based drug delivery with natural polymers (collagen, chitosan, etc.), synthetic polymers (PLGA, PCL), and inorganic materials (hydroxyapatite, bioactive glass), as well as nanocarriers (polymeric nanoparticles, liposomes, metallic nanoparticles) and stimulus-responsive hydrogels. Advanced approaches like growth factor gene delivery (using viral and non-viral vectors) and "smart" systems responsive to physiological cues are examined. Preclinical and clinical studies demonstrate that combining drug delivery with engineered scaffolds can significantly improve bone regeneration in challenging defects, though translational hurdles remain. Ongoing innovations including personalized 3D-printed scaffolds, multi-factor delivery, and AI-guided design – are poised to address current limitations. This integration of drug delivery and tissue engineering offers a powerful paradigm for bone regenerative therapy.

I. INTRODUCTION

Bone defects exceeding a critical size (generally >2 cm or a large segmental loss) do not heal spontaneously and pose major clinical challenge【8】. Worldwide, millions of bone graft procedures are performed annually bone grafts are the second most transplanted tissue after blood【1】【2】. The current gold-standard treatment for critical defects is autologous bone grafting, which provides osteogenic cells, growth factors, and an osteoconductive matrix. However, autografts are limited by donor site morbidity and supply constraints【3】【2】. Allografts and synthetic graft substitutes are alternatives but may integrate poorly or lack biological cues for complete regeneration【2】【8】.

Tissue engineering was introduced as a solution to generate biological bone substitutes【4】. In bone tissue engineering (BTE), three key elements osteogenic cells, scaffolding biomaterials, and signaling factors are combined to recapitulate bone healing【8】【4】. Successful bone regeneration requires a complex, well-orchestrated cascade of events involving inflammatory responses, vascularization, osteoprogenitor recruitment, and differentiation【5】【6】. In natural healing, growth factors (e.g. BMPs, FGFs, VEGF) are released in a spatially and temporally controlled manner to direct these processes【6】【7】. A major challenge is that

large defect sites lack sufficient levels of these regenerative signals【8】. Simply transplanting cells on scaffold may not be enough providing appropriate molecular signals (osteogenic, angiogenic, etc.) at the right time and location is crucial for successful integration and bone formation【5】【6】.

Drug delivery systems offer a strategy to enhance BTE by delivering growth factors, genes, or pharmaceuticals directly to the bone healing environment in a controlled fashion. Controlled delivery can augment osteoinduction and osteogenesis while avoiding the systemic side effects of high-dose therapies【9】【10】. This review provides a comprehensive overview of drug delivery strategies in BTE. We first outline the fundamentals of bone biology and healing relevant to regeneration. We then discuss conventional vs. localized drug delivery approaches and explore advanced systems: scaffold-based carriers, nanoparticles, hydrogels, and gene delivery vectors. Preclinical and clinical examples are highlighted to assess efficacy. Key challenges for translation (biocompatibility, release kinetics, manufacturing, regulatory issues) are examined, and emerging trends such as smart responsive systems, personalized scaffold design, and artificial intelligence (AI) integration are considered. By combining the principles of controlled drug release with tissue engineering, more effective therapies for challenging bone defects may be realized, moving closer to the goal of functional bone regeneration.

1.1 Objectives of the Review

The primary objectives of this review are:

- To provide a comprehensive overview of current drug delivery strategies applied in bone tissue engineering.
- To critically analyze conventional and advanced delivery systems, including scaffolds, nanoparticles, hydrogels, gene delivery, and smart responsive technologies.
- To highlight preclinical and clinical findings that demonstrate the translational potential of these systems.
- To identify the major challenges and limitations in achieving efficient, safe, and controlled drug delivery for bone regeneration.
- To propose future perspectives, including the integration of personalized medicine, AI-driven scaffold design, and next-generation responsive systems.

II. FUNDAMENTALS OF BONE TISSUE ENGINEERING

Bone Structure and Healing: Bone is a highly vascularized connective tissue with a hierarchical structure. Cortical bone (compact outer layer) provides strength and constitutes ~80% of adult skeletal mass, while cancellous bone (spongy inner trabecular bone) has high porosity and contributes to metabolic functions【8】. Bone naturally undergoes continuous remodeling and is capable of healing small fractures through a well-coordinated repair process. Classic fracture healing progresses through stages: an initial inflammatory phase, formation of a cartilaginous soft callus, mineralization into a hard callus, and remodeling of new bone to restore form and function【6】【7】. This regenerative process is driven by the recruitment of mesenchymal stem cells (MSCs) and the local release of growth factors (e.g. TGF-β, BMPs, VEGF) that promote osteogenic differentiation and angiogenesis【6】. However, when a bone defect is beyond a certain critical size (the minimum size that will not heal without intervention), the regenerative capacity is overwhelmed【8】. Such critical-sized defects often result in non-union, even with standard treatments, due to insufficient biological signaling and mechanical stability. Clinically, non-union rates of 5–10% are reported for fractures with risk factors, underscoring the need for enhanced therapeutic strategies【5】【1】.

Principles of Osteoconduction and Osteoinduction: Effective bone regeneration requires both an osteoconductive scaffold and osteoinductive signals. Osteoconduction refers to providing a 3D matrix or surface that supports the attachment and growth of bone-forming cells. Materials like natural bone mineral or bioactive ceramics are inherently osteoconductive【16】【17】. Osteoinduction is the process of inducing progenitor cells to differentiate into osteoblasts; this is typically achieved by growth factors such as bone morphogenetic proteins (BMPs)【12】. Urist's seminal discovery in 1965 demonstrated that demineralized bone matrix contains factors (later identified as BMPs) that can ectopically induce bone formation【12】. In designing tissue-

engineered constructs, the scaffold provides the osteoconductive environment, while delivered bioactive molecules provide the osteoinductive cues to stimulate new bone formation. Moreover, a healthy vascular supply (angiogenesis) and mechanical stimulation are important for functional regeneration【5】【34】. Therefore, BTE approaches often aim to incorporate vascular growth factors and consider mechanical properties of scaffolds to foster osseointegration and load-bearing capability.

Need for Controlled Delivery: In large defects, simply placing a scaffold or graft may not heal the bone unless the appropriate biological signals are present and sustained. Supraphysiological doses of growth factors delivered systemically or directly have been used clinically (e.g. recombinant BMP-2 in spinal fusion), but these can diffuse away quickly or cause adverse effects such as ectopic bone formation and inflammation【25】【26】. Consequently, there is great interest in localized and controlled delivery of drugs and growth factors within the defect site. Controlled release technology can mimic the natural spatiotemporal presentation of signals during bone healing【5】. By releasing osteogenic and angiogenic factors at optimal time points and concentrations, controlled delivery systems aim to enhance the body's regenerative response while minimizing complications. In the context of BTE, this often means integrating drug carriers with the scaffold or using smart biomaterials that respond to the healing environment (e.g. enzymes, pH) to trigger or modulate release【10】. The following sections will discuss how various drug delivery strategies are being applied to meet these design criteria in bone tissue engineering.

III. DRUG DELIVERY SYSTEMS IN BONE TISSUE ENGINEERING

3.1 Conventional Drug Delivery Approaches

Traditional drug therapies for bone conditions (such as systemic osteoporosis medications or systemic antibiotics for osteomyelitis) rely on oral or intravenous administration. While systemic delivery is non-invasive and suitable for diffusely distributed diseases, it is often suboptimal for localized bone repair. A major limitation is poor targeting efficiency to bone tissue【9】【10】. After systemic administration, only a small fraction of the drug may accumulate in the bone defect site, while the rest is distributed to non-target tissues. For example, systemic delivery of growth factors or cytokines often requires very high doses to achieve therapeutic levels in bone, leading to potential off-target effects (e.g. immune reactions, ectopic tissue formation)【10】. Bisphosphonates, used orally for osteoporosis, preferentially adsorb to bone mineral; even so, long-term use has been associated with systemic side effects (e.g. gastrointestinal irritation, atypical fractures) due to widespread drug exposure. Similarly, systemic antibiotics for bone infections must be given in high doses for extended periods, risking toxicity while sometimes failing to penetrate necrotic bone tissue in sufficient concentrations.

Another drawback of conventional systemic delivery is the lack of control over local drug kinetics. The drug is distributed via circulation and cleared according to its pharmacokinetics, which may not align with the temporal needs of bone healing. In many cases, the bone regenerative process would benefit from an initial burst of one factor (to recruit cells or blood vessels) followed by a longer sustained release of another factor (to promote differentiation), something not achievable with a single systemic dosage regimen. These limitations have motivated the development of targeted and localized delivery strategies. Approaches to improve systemic therapies include conjugating drugs with bone-seeking molecules such as tetracycline, bisphosphonates, or peptides that bind to bone mineral【9】【10】. Such targeting moieties can increase drug accumulation in skeletal tissues relative to other organs【10】. For instance, adding acidic oligopeptides or bisphosphonate groups to therapeutic molecules enhances their affinity for hydroxyapatite in bone, improving bone biodistribution【9】. Nonetheless, even with targeting, systemically delivered drugs typically still exhibit a majority of the dose in off-target sites (often <5–10% of injected dose accumulates in bone)【9】. Therefore, purely systemic approaches remain inadequate for complex bone regeneration scenarios that demand high local concentrations and multi-factorial cues.

In summary, conventional drug delivery provides limited spatial control and can lead to suboptimal concentrations at the bone defect or unwanted

systemic exposure. These challenges set the stage for localized drug delivery strategies, where the therapeutic agents are placed directly at the defect site. By localizing treatment, one can achieve effective concentrations in the bone microenvironment while reducing systemic side effects. The next section discusses such localized approaches and how they compare to systemic delivery.

3.2 Localized Drug Delivery

Localized delivery involves placing a drug depot or controlled-release system directly at the bone defect during surgery. This approach ensures a high concentration of therapeutics in the target site and sustained availability during the healing period. Clinically, a simple example is the use of antibiotic-impregnated bone cement or beads for osteomyelitis treatment, which releases antibiotics locally to eradicate infection. In the context of bone regeneration, the most prominent example is the use of a collagen sponge soaked with recombinant human BMP-2, as employed in the INFUSE™ bone graft product【26】. In such a device, the scaffold (an absorbable collagen sponge) serves as a carrier to hold BMP-2 at the defect site after implantation. This localized BMP-2 delivery shown to significantly enhance bone formation and spinal fusion rates compared to graft alone【26】. However, first-generation local delivery systems like the collagen sponge are relatively primitive in their release profile – they tend to release a large burst of the protein within the first few days and very little thereafter【25】. Studies have found that collagen sponges can lose the majority of their BMP-2 payload within one to two weeks, with less than ~10% remaining by that time【25】. The initial burst can lead to very high local BMP-2 concentrations, which have been linked to complications such as inflammatory swelling or unwanted bone formation in adjacent tissues (e.g. ectopic bone or spinal canal bone overgrowth)【25】

Thus, while localized delivery is a powerful approach, it benefits greatly from incorporating controlled release mechanisms to modulate the timing and dose of factor presentation.

Researchers have developed various controlled-release depots for localized delivery in bone. A basic strategy is to embed the drug in a biodegradable matrix (scaffold, cement, hydrogel, or microsphere) that slows its diffusion. For example, BMP-2 or VEGF can be encapsulated in polymer microspheres (like PLGA) and then dispersed in a scaffold; the polymer's degradation kinetics then govern the release over weeks. Such composite systems have shown more sustained release and often improved bone regeneration outcomes compared to immediate-release devices【14】【24】. In one study, a critical femoral defect treated with BMP-2 encapsulated in an alginate hydrogel showed more controlled release and greater bone volume after 8–12 weeks than BMP-2 delivered on a collagen sponge【24】. The controlled release reduced the need for an excessive initial dose and resulted in more uniform bone formation confined to the defect site (whereas the burst from collagen led to some heterotopic ossification)【24】.

Another advanced concept is stimuli-responsive local delivery, where the release rate adjusts to the healing environment. For instance, enzyme-responsive hydrogels have been designed to release growth factors in response to matrix metalloproteinases (MMPs) secreted during bone remodeling【10】. In one approach, BMP-2 was tethered in a PEG hydrogel via peptide linkers that are cleaved by MMPs expressed by infiltrating cells; as the tissue remodels and produces MMPs, the gel degrades and releases BMP-2 in situ【10】. This couples the drug release to the stage of healing an elegant form of "smart" delivery. Similarly, pH-responsive vehicles have been explored to treat bone infections like osteomyelitis, where the local environment is acidic. For example, antibiotics loaded in a pH-sensitive polymer were released faster in acidic pH (~pH 5) found in infection sites, but more slowly at normal physiological pH【10】. This means an infected, acidic bone site would trigger rapid drug release for therapy, whereas healthy tissue would not, thereby concentrating the drug action where needed.

Compared to systemic administration, localized delivery can achieve far higher local drug levels without systemic toxicity. It often requires an invasive step (surgical implantation), but given that many critical defects are managed surgically with scaffolds or fixation devices, incorporating a drug depot at the time of surgery is clinically feasible. In fact, many tissue-engineered bone implants are inherently localized delivery systems (a scaffold that also delivers cells or factors). The following sections delve

into the specific types of drug delivery systems used in BTE, including scaffold-based systems, nanoparticles, hydrogels, and gene delivery vectors, detailing how each can be applied to promote bone healing.

IV. ADVANCED STRATEGIES FOR DRUG DELIVERY

4.1 Scaffold-Based Drug Delivery

Scaffold-based systems are central to bone tissue engineering, as the scaffold provides a structural framework for new bone growth. By integrating drug delivery into the scaffold, one can create an osteoconductive matrix that also releases osteoinductive or other therapeutic agents. An ideal bone scaffold is biocompatible, biodegradable, highly porous (to allow cell invasion and vascularization), mechanically competent, and able to deliver bioactive cues【11】【8】. A wide variety of biomaterials have been employed to fabricate such scaffolds, broadly classified into natural polymers, synthetic polymers, and inorganic/bioactive ceramics.

Natural Polymer Scaffolds: Natural biomaterials like collagens, glycosaminoglycans, and polysaccharides inherently resemble the extracellular matrix (ECM) and often exhibit good biocompatibility and cell affinity. Collagen, the primary organic component of bone matrix, is a common scaffold material (e.g. type I collagen sponges). Collagen scaffolds are osteoconductive and have been used clinically to carry BMP-2, as mentioned above【26】. They can also be combined with minerals to improve mechanical strength (for example, collagen-hydroxyapatite composites). Chitosan, a polysaccharide derived from chitin, is another natural polymer widely studied for bone scaffolds. Chitosan is biodegradable and can support osteoblast attachment and mineralized matrix formation【13】. Its cationic nature allows it to bind growth factors and DNA, making it useful for delivering molecules. For instance, chitosan sponges or fibers have been loaded with BMP-2 or TGF-β and shown to induce bone formation in vivo【13】. Other natural polymers include alginate (a seaweed-derived polysaccharide) which can form hydrogels or foams for bone repair, and silk fibroin from silkworm silk, which has excellent mechanical properties and biocompatibility. These natural matrices often have intrinsic biological motifs that cells recognize (e.g. RGD sequences in collagen and fibronectin), promoting cell adhesion and differentiation. However, natural materials can have variability and sometimes inferior mechanical strength, so they are often reinforced or combined with ceramics.

Synthetic Polymer Scaffolds: Synthetic polymers offer more tunable properties and reproducibility. Aliphatic polyesters such as poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and polycaprolactone (PCL) are popular choices that are FDA-approved for certain uses. They degrade by hydrolysis into biocompatible byproducts and their mechanical properties can be tailored by molecular weight and crystallinity【14】. PLGA scaffolds (fabricated by techniques like porogen leaching or 3D printing) have been used to deliver a variety of drugs. The polymer's degradation rate (spanning weeks to months provides a sustained release of any embedded growth factor or small-molecule drug【14】. For example, a porous PLGA scaffold loaded with antibiotics showed gradual local drug release and successfully treated an infected bone defect in an animal model【10】. PCL is a slower-degrading polymer (often over many months) with good toughness, making it suitable for load-bearing scaffold designs【15】. PCL scaffolds (including those made by 3D printing) investigated for long-term delivery of factors like BMP-2 or vascular endothelial growth factor (VEGF) during bone regeneration【15】. Additionally, synthetic polymers like poly(ethylene glycol) (PEG) are used in hydrogels and as injectable carriers (discussed in Section 6.3), and polyurethane or polycarbonate urethanes have been explored for their elastomeric properties in mimicking bone's flexibility. One can also graft bioactive molecules onto synthetic polymers for instance, RGD peptides to promote cell adhesion or heparin to bind growth factors combining the benefits of synthetic control and biological activity【11】. The versatility of synthetic polymers allows for creating composite scaffolds: e.g. PLGA or PCL combined with bioactive particles for improved osteoconduction and drug loading capacity.

Bioactive Ceramics and Composite Scaffolds: Inorganic materials like calcium phosphates are inherently osteoconductive and have a long history in bone graft substitutes【16】【17】. Hydroxyapatite (HA), the mineral phase of bone, and beta-tricalcium phosphate (β-TCP) are two common examples. These

ceramics can be formed into porous scaffolds or used as coatings/particles within polymer scaffolds. They slowly dissolve in the body, releasing calcium and phosphate ions that can stimulate bone mineralization. Importantly, they can also serve as carriers for drugs: the ceramic surface can adsorb proteins and drugs, or drugs can be physically entrapped in their porous structure. However, without further modification, pure ceramic scaffolds often result in an initial burst release of adsorbed drugs. To achieve a more controlled release, ceramics are frequently combined with polymers (forming composite scaffolds) or fabricated with drug-loaded micropores. Bioactive glass is another inorganic material – it's an amorphous silica-based glass that bonds to bone and can stimulate osteoblasts. Bioactive glass scaffolds (e.g. 45S5 Bioglass) shown the ability to stimulate osteogenesis and can be loaded with growth factors or antibiotics which leach out as the glass dissolves【17】. For example, bioactive glass bone fillers loaded with gentamicin have been used clinically for local antibiotic delivery in bone infections. Composite scaffolds, such as collagen or chitosan combined with HA or bioglass, leverage the organic component's drug delivery capabilities and the inorganic's osteoconductivity【13】【16】. These composites can achieve mechanical properties closer to bone and can simultaneously deliver multiple agents (e.g. a growth factor bound to the polymer phase and an antibiotic in the ceramic phase).

In all these scaffold-based systems, the release kinetics are a function of scaffold degradation, diffusion through the scaffold pores, and the binding interactions between the drug and scaffold matrix. By tuning material properties (polymer composition, crosslink density, ceramic content, etc.), one can modulate how fast the scaffold releases its cargo. For instance, increasing the ratio of glycolic acid in PLGA makes it degrade faster and release encapsulated drugs sooner【14】. Incorporating a mineral like HA, which can bind growth factors, may prolong the release by reversible adsorption of the protein. Table 1 in various studies summarizes that natural polymers typically allow a rapid but biofriendly release, synthetic polymers provide programmable sustained release, and ceramics contribute to long-term support and secondary ion-mediated stimulation of bone formation【14】【16】.

Table 1. Comparison of scaffold materials and release kinetics in bone tissue engineering

Scaffold Type	Example Materials	Advantages	Limitations	Typical Release Kinetics	References
Natural polymers	Collagen, chitosan, alginate	Biocompatible, mimic ECM, inherent bioactivity	Variable mechanical strength, batch-to-batch variability	Fast–moderate (days–weeks)	[13][26]
Synthetic polymers	PLGA, PLA, PCL, PEG	Tunable degradation, reproducible, scalable	Acidic byproducts (PLGA), bio-inert unless modified	Sustained (weeks–months)	[14][15]
Ceramics	Hydroxyapatite, β-TCP, bioglass	Osteoconductive, strong, bioactive ions release	Brittle, slow degradation	Prolonged, months–years (adsorption-based)	[16][17]
Composites	PLGA/HA, collagen/bioglass	Combine strength + bioactivity, multi-agent delivery	Fabrication complexity	Programmable dual-phase release	[13][16]

In summary, scaffold-based drug delivery in BTE provides an integrated approach: the scaffold secures the drug at the defect and guides tissue growth, while the drug (or multiple drugs) actively directs cellular behaviors. Numerous studies have demonstrated superior bone healing when scaffolds are loaded with growth factors or other drugs, compared to scaffolds alone【24】【25】. The next subsections will cover more specialized delivery vehicles (nanoparticles and hydrogels) which can be used standalone or in conjunction with scaffolds.

4.2 Nanoparticle-Mediated Delivery

Nanoscale delivery systems have gained attention for bone regeneration due to their high surface area, tunable functionalization, and ability to penetrate tissue matrices. Nanoparticles (NPs) in various forms metallic, ceramic, polymeric, and lipid-based can be designed to carry therapeutic payloads and home to bone tissue【17】【18】. They are often used as components of a larger scaffold or injectable formulation, but can also be delivered via injection to target bone (with appropriate surface modifications).

Metallic and Inorganic Nanoparticles: Metallic NPs such as gold (Au) and silver (Ag) have unique properties that can be leveraged in bone therapy. Silver nanoparticles are well-known for their antibacterial activity; incorporating Ag NPs into bone graft materials can help prevent or treat infections at the defect site【17】. For example, a scaffold doped with silver NPs can locally release Ag ions that kill bacteria, protecting the regenerating bone from infection. Gold nanoparticles (AuNPs) are chemically inert but have excellent protein adsorption capability and can modulate cell behavior. Studies have shown that AuNPs can promote osteogenic differentiation by acting as delivery vehicles for osteoinductive proteins or as photothermal agents to stimulate cells【18】. Their surfaces can be functionalized with targeting ligands (like peptides that bind bone mineral) or loaded with DNA/RNA for gene delivery. For instance, gold NPs functionalized with a peptide coating have been used to deliver siRNA specifically to osteoblasts and augment bone formation【18】. Additionally, because metal NPs have unique optical responses, AuNPs have been used in combination with external stimuli (like near-infrared light) to trigger on-demand release of tethered growth factors in a scaffold upon light exposure – although such approaches are still experimental. Another inorganic nano-carrier is calcium phosphate nanoparticles, essentially the mineral component at the nano-scale, which can carry drugs like antibiotics or siRNA through adsorption and release them as they dissolve, all while being bioactive toward bone cells【17】. These inorganic NPs not only deliver drugs but also provide osteoconductive signals by releasing Ca^{2+} ions that can stimulate bone mineralization.

Polymeric Nanoparticles and Micelles: Biodegradable polymer NPs (typically made from PLGA, PLA, or poly(ester-anhydride) compounds) are widely studied for controlled drug release. When used in bone engineering, polymeric NPs can be injected or incorporated into scaffolds to provide a sustained release of growth factors, anti-resorptive drugs, or genetic material. For example, PLGA nano- or microspheres loaded with BMP-2 have been embedded in collagen or ceramic scaffolds to create a slow-release system that significantly improved bone healing in large defects【14】【24】. Compared to loading the BMP directly onto the scaffold, the NP encapsulation reduces the burst release and protects the growth factor from rapid inactivation. Similarly, polymeric micelles which are self-assembled nanocarriers formed by amphiphilic block copolymers (like PEG-PLA) can solubilize hydrophobic drugs (such as certain steroid hormones or anti-inflammatory drugs) and have been used to deliver such agents to bone tissue in animal models of osteoporosis【19】. These micelles or NPs can be surface-functionalized with bone-targeting groups (like bisphosphonates) to increase their accumulation in bone lesions【10】. In one strategy, liposomes (phospholipid-based spherical nanocarriers) derivatized with alendronate (a bisphosphonate) were used to carry anti-cancer drugs to bone metastases, capitalizing on the high affinity of bisphosphonates for bone mineral【10】. In the bone regeneration context, liposomes have been used to deliver growth factors like BMP-2 or growth factor genes. For instance, one study encapsulated BMP-2 in liposomes within a fibrin gel and demonstrated enhanced localized bone formation with a controlled release profile【19】. Polymeric NPs are advantageous for their tunable degradation (which governs release timing) and capacity to co-deliver multiple agents (by encapsulating one drug in the core and another on the surface, for example).

Stimuli-Responsive and Composite Nanocarriers: Advanced nanocarriers can respond to stimuli such as pH, temperature, magnetic fields, or ultrasound to trigger or enhance drug release. In bone repair, one novel example involved ultra-sonic stimulation: researchers developed liposome-coated microbubbles carrying BMP-2 that would release the growth factor upon exposure to an external ultrasound signal【20】 This approach could allow surgeons to “on-demand” release a dose of growth factor in the weeks following

surgery by applying ultrasound at the defect site, thereby giving temporal control beyond the initial implantation. Another approach used superparamagnetic iron-oxide nanoparticles embedded in scaffolds, which can generate heat under an alternating magnetic field; this mild heating can trigger faster drug diffusion or gel degradation to release drugs in a spatiotemporally controlled way【17】. Although these techniques are in early stages, they illustrate the potential of smart nanoparticle systems to deliver therapeutic signals in sync with healing or external cues.

Overall, nanoparticle-mediated delivery contributes significantly to bone tissue engineering by enabling multi-functional scaffolds. NPs can impart antimicrobial properties, enhance mechanical properties (e.g. silica NPs reinforcing a polymer scaffold), and provide controlled release of bioactive molecules【17】【20】. A scaffold loaded with, say, antibiotic-releasing and growth-factor-releasing NPs can concurrently fight infection and stimulate bone growth. One must consider, however, the biocompatibility of nanoparticles themselves some metallic NPs in high concentrations can be cytotoxic or inflammatory. Therefore, dosing and release kinetics are designed to keep NP levels safe while accomplishing the therapeutic purpose. Many studies report that integrating nano-delivery systems leads to faster and more robust bone regeneration compared to plain scaffolds, underlining the synergy between nanoscale drug delivery and bone tissue engineering【17】【18】.

4.3 Hydrogel-Based Delivery

Hydrogels are hydrophilic polymer networks capable of holding large amounts of water, often forming a gel mimicking the consistency of soft tissues. In bone repair, hydrogels have attracted attention as injectable carriers and as cell/drug delivery matrices that can fill irregularly shaped defects. An injectable hydrogel can be introduced minimally invasively (via syringe) and then solidify in situ to conform to the defect geometry【21】. This approach is beneficial for complex craniofacial or load-bearing sites where prefabricated scaffold shapes may not perfectly fit the defect. Common hydrogel materials for bone applications include naturally derived polymers like gelatin, collagen, chitosan, alginate, and hyaluronic acid, as well as synthetic or semi-synthetic polymers like PEG-based hydrogels and self-assembling peptides【21】.

Injectable and In Situ Gelling Systems: Some hydrogels are liquids at room temperature but gel at body temperature (thermosensitive), or gel upon mixing of two components (as in two-part crosslinking systems using fibrin or injectable calcium phosphate cements). For example, an alginate or chitosan solution mixed with calcium ions will quickly form a gel (ionically crosslinked) that can hold cells and drugs in the bone defect. These hydrogels can serve as a depot for growth factors: one can pre-mix BMP-2, for instance, into a temperature-sensitive hydrogel (like one based on PLGA-PEG-PLGA triblock copolymer) and inject it into a bone cavity, where it gels and slowly releases BMP-2 over time【21】. Hydrogels generally offer gentle encapsulation conditions (important for proteins' bioactivity and cell viability) and diffusion-based release. By adjusting polymer concentration and crosslink density, the release profile can be tuned loosely crosslinked gels give faster release, while tightly crosslinked ones prolong it. One challenge is that many hydrogels release their payload relatively quickly (within days) unless modified, due to high water content and pore size. Nonetheless, chemical modifications like heparin conjugation (to bind growth factors) or nanoparticle additives can slow the diffusion and achieve weeks of release【19】.

Stimuli-Responsive Hydrogels: Hydrogels can be engineered to degrade or release drugs in response to specific stimuli in the bone healing milieu. As noted earlier, enzyme-sensitive hydrogels employ peptide linkers cleavable by MMPs or alkaline phosphatase (ALP), enzymes active during bone regeneration. One example is a PEG hydrogel crosslinked with peptides that degrade when cleaved by MMP-2 and MMP-9 enzymes upregulated by inflammatory and bone-forming cells. When MSCs and macrophages infiltrate the hydrogel and secrete MMPs, the hydrogel gradually disintegrates, releasing embedded growth factors in synchrony with cellular invasion【10】. Another approach is pH-responsive hydrogels that dissolve faster in low pH. In a bone infection scenario, the local pH can drop to ~5–6; a hydrogel formulated with acid-cleavable bonds or pH-sensitive linkages will accelerate drug release under those conditions【22】. Xue et al. demonstrated an injectable

hydroxyapatite–chitosan composite cement that provided sustained release of an antibacterial enzyme (lysostaphin) and showed faster enzyme release under acidic conditions associated with infection【22】. This smart release both treated the infection and subsequently allowed bone regeneration once the infection resolved. Thermally responsive hydrogels (e.g. those with lower critical solution temperature around 37°C) can also be used to trigger release with mild heating, though in bone applications this is less common unless external stimuli (like focused ultrasound or heat) are applied.

Hydrogels can also be used as cell carriers in cell-based therapies. For instance, MSCs can be suspended in a BMP-2-containing hydrogel and injected into a defect; the hydrogel protects the cells and co-delivers the growth factor to induce their osteogenic differentiation【21】. In such cases, the hydrogel degradation rate is important: it should allow eventual cell-mediated remodeling and not impede the formation of new bone tissue. Many hydrogels are designed to degrade either by hydrolysis or cell-secreted enzymes on the order of a few weeks to months, ideally matching the rate of new tissue formation.

One of the advantages of hydrogels in drug delivery is their ability to provide a relatively homogeneous and sustained release, as the drug diffuses through the gel matrix. They cause minimal mechanical irritation (being soft and tissue-like) and can be engineered to match the viscoelastic properties of native bone marrow or cartilage, which is beneficial in joint or osteochondral defect repair【21】. However, pure hydrogels often lack the mechanical strength of solid scaffolds. In weight-bearing cortical bone defects, hydrogels are commonly used in combination with a sturdier scaffold or mineral phase – for example, a hydrogel might fill the interior of a stiff 3D-printed scaffold to provide bioactive delivery, or composite hydrogels with ceramic particles might be used to reinforce the matrix【22】.

In summary, hydrogel-based delivery systems offer a flexible platform for delivering a variety of therapeutics (proteins, small molecules, genes, even cells) to bone defects in a minimally invasive way. They excel in adaptable form factors and responsive behavior. Clinical translations of hydrogels include products like injectable bone graft substitutes (some based on polymer/collagen gels with calcium phosphate) that set in situ and release growth factors. The continued development of injectable, patient-specific hydrogel therapies could significantly simplify surgical procedures for bone regeneration and improve outcomes by ensuring that regeneration-promoting signals are present throughout the healing timeline【21】.

4.4 Gene and Growth Factor Delivery

Delivering osteogenic growth factors and genes is a cornerstone of regenerative strategies in bone engineering. Growth factors such as BMP-2, BMP-7 (osteogenic), VEGF (angiogenic), FGF-2, PDGF, and TGF-β have been extensively studied for their ability to stimulate bone formation and vascularization. Instead of repeated protein injections (which are costly and have short half-lives in vivo), controlled delivery systems are used to present these growth factors at the defect site in a sustained manner. As discussed, scaffolds or carriers loaded with recombinant growth factors can dramatically enhance bone healing – BMP-2 on a collagen sponge is an FDA-approved therapy for certain spinal fusions and tibial nonunions【26】. Likewise, PDGF has been used in the clinic (e.g. in beta-tricalcium phosphate matrix) to promote bone repair in orthopedic and dental applications【29】. The challenge with growth factor delivery is achieving the right dose over the right duration. Too low and there is no effect; too high and one risks aberrant bone or immune reactions. Controlled-release matrices (like those described in sections 5.2 and 6.1–6.3) help maintain therapeutic levels locally. For example, delivering BMP-2 in a depot that releases it over 2–4 weeks (rather than mostly in the first day) leads to more effective bone induction with lower total dose【24】. Additionally, combinatorial delivery of multiple factors is often more effective than single-factor delivery. Bone regeneration benefits from an early angiogenic stimulus (to form blood vessels) followed by an osteogenic stimulus. Studies have shown that co-delivery of VEGF and BMP-2 leads to more robust bone formation than either alone, due to the coupling of angiogenesis and osteogenesis【30】. A scaffold can be engineered to release VEGF quickly (within the first week) and BMP-2 more slowly over several weeks【30】. Such sequential release can be achieved by, for instance, using a fast-degrading polymer for

VEGF and a slow-degrading polymer or stronger binding for BMP-2 in the same construct.

Instead of or in addition to proteins, the field is exploring gene therapy approaches, delivering DNA or RNA that encode regenerative factors so that the patient's own cells produce the stimulus. Gene delivery can be achieved via viral vectors (like adenovirus, adeno-associated virus, lentivirus) or non-viral vectors (plasmid DNA, polyplexes, lipoplexes, or emerging CRISPR systems). Viral BMP gene therapy was demonstrated in landmark preclinical studies where adenoviruses encoding BMP-2 were injected into skeletal muscle or defects, leading to local BMP-2 production and new bone formation【32】. Lieberman et al. showed that marrow stromal cells transduced ex vivo with an adenoviral BMP-2 vector could heal critical-sized femoral defects in rodents when implanted【32】. Direct in vivo injection of BMP-2 adenovirus also induced bone, though control of spatial targeting is a concern. Non-viral plasmid delivery of growth factor genes (like plasmid encoding VEGF, delivered in a scaffold) has been tested with some success, although the efficiency is much lower than viral methods. The advantage of gene delivery is a sustained endogenous production of the factor potentially for weeks – which might better mimic natural healing. The downside is the difficulty in dosing (gene expression might be too high or too low, and is hard to turn off) and safety issues (with viral vectors, potential immune response or insertional mutagenesis; with plasmids, low transfection rates).

Researchers have also employed RNA interference (RNAi) and microRNAs to enhance bone regeneration by silencing negative regulators or modulating differentiation pathways. For example, siRNA against a bone formation inhibitor (such as Noggin, a BMP antagonist) has been delivered via PEI nanoparticles or liposomes to bone injuries, resulting in elevated BMP activity and improved healing【29】. These nucleic acid therapies require delivery systems to protect them from degradation and facilitate cellular uptake. Lipid nanoparticles and polymer complexes are commonly used to deliver siRNA to bone tissue; targeting ligands (like aptamers or peptides) can increase uptake by osteoblasts or marrow stromal cells【18】.

A frontier area is applying CRISPR/Cas9 gene editing to bone repair. With CRISPR, one could permanently knock out genes that impede healing (for example, genes promoting fibrosis or bone resorption) or knock-in/activate genes that enhance osteogenesis. Recent studies have used CRISPR activation (CRISPRa) to upregulate endogenous osteogenic factors in MSCs: for instance, co-activation of Wnt10b and Foxc2 genes in MSCs via CRISPRa significantly enhanced their osteogenic differentiation and improved calvarial defect repair in mice【29】. Such ex vivo gene-edited MSC therapy or even in situ CRISPR delivery might in the future allow precise control of the bone regeneration program. However, CRISPR delivery faces the same hurdles of gene therapy needing safe vectors and efficient in vivo delivery. Biomaterial scaffolds are being investigated as platforms to deliver CRISPR components locally in bone defects, thereby limiting gene editing to the target site【29】.

In summary, growth factor delivery (protein or gene-based) is a powerful strategy to induce bone formation. BTE constructs often incorporate one or more of these signals: for example, a scaffold might be loaded with BMP-2 protein for immediate effect and plasmid DNA for sustained VEGF production over a longer term. The combination of vascular and osteogenic factors has repeatedly shown synergistic effects【30】. Another combination is osteogenic and anti-resorptive or anti-inflammatory agents: e.g. BMP-2 plus a bisphosphonate drug can both spur formation and reduce early resorption of graft, leading to net bone gain. Additionally, an emerging theme is immunomodulatory factor delivery since the initial immune response to an implant greatly affects healing outcome, some strategies deliver cytokines or immunomodulatory drugs to induce a pro-healing inflammatory profile (e.g. M2 macrophage polarization) that supports bone regeneration【35】. This can be considered an extension of growth factor delivery, targeting the immune environment.

Ultimately, whether using recombinant proteins, gene therapy vectors, or gene editing tools, the goal is to provide the necessary signals in a controlled way to recapitulate the developmental processes of bone formation. The success of BMP-2 and BMP-7 in certain clinical contexts validates the concept, but also warns that dosing and delivery format are critical BMP-7 (OP-1) putty was approved for bone repair but saw limited use due to high cost and variable outcomes, and was eventually withdrawn from some

markets. Careful design of delivery systems aims to maximize therapeutic efficacy while minimizing risks, which is why next-generation scaffolds are incorporating smarter and more localized gene/factor delivery approaches rather than relying on systemic or repeated administrations【26】【29】.

4.5 Smart and Responsive Delivery Systems

"Smart" delivery systems refer to those that can respond to environmental cues or external triggers to modulate drug release. In bone tissue engineering, such systems are particularly valuable because the healing process is dynamic the ideal timing for releasing a certain factor may depend on the stage of healing or presence of certain cells. We have touched on some responsive systems already (enzyme-responsive hydrogels in section 6.3, pH-responsive microspheres in 5.2, ultrasound-triggered liposomes in 6.2). Here we consolidate these concepts and also consider advanced fabrication technologies enabling smart delivery, such as 3D printing for personalized implants.

Stimuli-Responsive Carriers: These carriers remain inert until exposed to a specific stimulus, at which point they change behavior to release the drug. Internal stimuli harness the bone healing environment for example, an inflammation-responsive system might release an anti-inflammatory drug when inflammation is high, then stop releasing as inflammation subsides. One could use a hydrogel that degrades faster in the presence of reactive oxygen species (ROS), which are abundant during acute inflammation, thereby delivering, say, an anti-oxidant or anti-inflammatory during early injury phase. For bone anabolic therapies, mechanical stimuli can also be used. Researchers have developed mechanosensitive drug delivery coatings that release more drug under cyclic loading. Although still experimental, the concept is to take advantage of the fact that rehabilitation exercises or micromotion at the implant could "massage" the drug out of a scaffold when needed. Magnetic-field-responsive systems use magnetic nanoparticles embedded in a scaffold; when an external magnetic field is applied, the particles heat slightly or vibrate, accelerating matrix degradation or drug diffusion【17】. This can be done non-invasively from outside the body to trigger on-demand release in deep sites. For example, a composite scaffold with magnetic nano-hydroxyapatite and a thermo-responsive polymer could be loaded with growth factor; upon applying a magnetic field, the induced heat softens the polymer and releases a pulse of growth factor. While not in clinical use yet, this kind of remote control over drug delivery in an implant is a "smart" capability being explored.

3D-Printed and Micro-Architected Scaffolds: Advances in additive manufacturing (3D printing) allow fabrication of patient-specific scaffolds with complex internal architectures. This has two implications for drug delivery: (1) Personalized scaffold shape for an anatomically precise fit improves the mechanical environment and could reduce the need for extensive fixation, indirectly promoting healing; (2) Spatial patterning of drug distribution becomes possible. Using multi-material 3D printing, one can create a scaffold where certain regions contain drug-loaded bioinks and others do not. This could, for example, concentrate antibiotics on the periphery of an implant (to prevent infection from surrounding tissue) and growth factors in the center (to stimulate bone ingrowth)【25】. Furthermore, gradient delivery is achievable a scaffold could have a higher concentration of VEGF on the outer regions to encourage vessel infiltration, and higher BMP-2 deeper inside for osteogenesis after vessels have formed. 3D printing also enables creation of intricate pore architectures that can modulate the release rate (by controlling surface area and connectivity). Studies using triply periodic minimal surface (TPMS) scaffold designs have shown that pore size and topology affect cell migration but also how fluids (and thus dissolved drugs) diffuse through the scaffold【28】. By computationally optimizing these designs (often with AI and topology optimization algorithms【28】), scaffolds can be "programmed" to release drugs at desired rates or sequences. For instance, a recent work used machine learning to design a lattice that provided an optimal dual release profile for two growth factors, matching the predicted ideal temporal profile for bone formation【28】. These approaches remain in development, but showcase the merging of smart design and manufacturing with drug delivery.

Combined Delivery of Multiple Agents: "Smart" can also imply delivering multiple therapeutics in a coordinated way. Dual and multi-drug delivery systems are being actively researched for bone. We have discussed synergistic pairs like BMP-2 + VEGF

and BMP-2 + antibiotics. A sophisticated system may have two separate release vehicles within one scaffold – e.g. fast-release alginate microspheres for VEGF and slow-release PLGA microspheres for BMP-2 embedded in the same scaffold【30】. The smart aspect is designing these so that one factor's release triggers or complements the other's effect. In the case of BMP-2 plus lysostaphin (an antibiotic enzyme), a recent study encapsulated lysostaphin in a hydrogel and co-delivered BMP-2; the enzymatic release cleared Staphylococcus infection in the bone, after which BMP-2 induced healing of the once-infected defect【28】. This dual-delivery approach addressed two problems (infection and non-union) simultaneously in a coordinated fashion. As a result, previously refractory infected bone defects showed robust regeneration【28】.

Integration with Regenerative Medicine and Immunomodulation: Future smart delivery systems will likely integrate immunomodulatory cues as well – for example, releasing factors that recruit anti-inflammatory M2 macrophages initially, then later releasing factors for osteoblast differentiation. The concept of a "smart scaffold" is one that adapts to the evolving tissue environment: sensing (or at least being designed for) changes in pH, enzymes, or mechanical load, and responding by delivering the appropriate biological stimuli. Some experimental scaffolds incorporate feedback systems (using, say, peptide linkers that are only cleaved when specific cell types are present). While true self-regulating scaffolds are still rare, the combination of sequential delivery, stimulus-responsiveness, and multi-therapeutic capacity is moving the field toward more life-like regenerative systems.

Another layer of smart technology is AI-driven design of drug delivery scaffolds. Machine learning algorithms have been employed to analyze vast datasets of biomaterial properties and biological outcomes, helping to identify key design parameters for optimal healing【28】. AI can also assist in personalized medicine: given a patient's data (age, defect size, comorbidities), an AI model might predict the ideal release profile or drug combination needed, and then a 3D printer could fabricate a scaffold with those specifications. Though in early stages, such approaches exemplify the merging of computational intelligence with smart drug delivery in BTE.

In summary, smart and responsive delivery systems in bone tissue engineering seek to provide the right therapeutic signals at the right time and place, in tune with the patient's healing process. Whether through material responsiveness to the local bone milieu or external triggers, or through advanced scaffold patterning and multi-drug orchestration, these systems represent the cutting edge aimed at maximizing efficacy and safety of regenerative bone therapies.

Preclinical and Clinical Studies

Significant progress has been made in validating drug-enhanced bone tissue engineering strategies in vivo. In vitro studies initially demonstrate that adding controlled-delivery of osteogenic factors to scaffolds can induce MSC differentiation to osteoblasts and robust mineral deposition, compared to scaffolds without factors【13】【14】. These encouraging results have translated into numerous preclinical animal studies in rodents, rabbits, and larger animals (sheep, dogs, primates). For example, a classic mouse study by Boerckel et al. showed that a PLGA scaffold delivering BMP-2 via alginate microbeads healed a critically-sized femoral defect in mice, whereas the same scaffold without BMP-2 did not【24】. The bone regenerated with the BMP-2 release was biomechanically functional. In a rat model of spinal fusion, hydrogels delivering BMP-2 achieved successful vertebral fusion in a high percentage of animals, similar to the clinical gold standard BMP-2 on sponge, but using an order of magnitude lower dose【25】. In rabbits, dual delivery of VEGF and BMP-2 from a porous scaffold led to more mature and vascularized bone in segmental defects at 8 weeks post-surgery, compared to BMP-2 alone which yielded bone of poorer quality due to insufficient vasculature【30】. Large-animal studies are particularly important for clinical translation: one notable case is a sheep tibial defect study, where a 3D-printed titanium scaffold coated with collagen hydrogel releasing BMP-2 resulted in bridging of a 30 mm defect in 3 months, with the healed bone sustaining weight-bearing function【34】. By contrast, sheep receiving the scaffold without BMP-2 showed only partial healing at the defect ends【34】. Another large-animal trial in goats used gene therapy – adenoviral BMP-7 delivered on a scaffold – to heal critical femur

defects, the feasibility of ex vivo gene-enhanced implants in a clinically relevant setting【32】.

Several clinical studies and cases have emerged, though clinical adoption of tissue-engineered drug delivery constructs is still in early phases. The use of BMP-2 (INFUSE) and BMP-7 (OP-1) in collagen or ceramic carriers provided early validation that growth factor delivery can significantly improve bone healing in humans【26】【29】. INFUSE (rhBMP-2 on collagen) has been successfully used in thousands of spinal fusion patients, achieving higher fusion rates and faster healing autografts in some contexts【26】. However, issues such as inflammation, ectopic bone, and cost have tempered its use. OP-1 (rhBMP-7 in collagen) was approved for recalcitrant long-bone nonunions and showed good healing rates in clinical studies, though its use diminished after BMP-7 production ceased. More advanced products are in the pipeline: one example is a dual-factor scaffold for orthopedic trauma, combining PDGF and IGF-1 in a polymer/ceramic matrix, which has entered clinical trials for accelerating fracture repair. Another is a cell-based gene therapy: bone marrow MSCs transduced with a BMP-2 gene, delivered on a scaffold, which has been tested in a small human trial for long bone nonunions initial reports indicated improved healing in cases that previously had multiple failed surgeries【24】. Quarto et al.'s pioneering 2001 report demonstrated that culture-expanded autologous MSCs on a HA/TCP scaffold could repair a large segmental defect in a human radius, producing cortical bone bridging the gap【24】. While that case did not involve exogenous drug delivery (the cells provided growth factors endogenously), it proved the tissue engineering concept in a clinical scenario. Building on that, newer studies are incorporating controlled release of growth factors to support the transplanted cells.

Another clinical application area is in dentistry and oral surgery: growth factor delivery scaffolds (e.g. PDGF in a beta-TCP matrix, marketed as GEM 21S) have been used to regenerate periodontal bone defects with success【29】. Also, localized antibiotic release devices are in clinical use for bone infections one example being calcium sulfate beads impregnated with antibiotics used to fill infected cavities after debridement, providing local high antibiotic levels that help eradicate osteomyelitis without systemic toxicity. The combination of such antibiotic beads with bone growth factors is under investigation to treat infected nonunions, a very difficult clinical scenario【28】.

Regulatory and ethical considerations inevitably come into play as these technologies progress. The use of high doses of potent morphogens like BMP-2 raised safety flags, leading regulatory agencies to scrutinize these combination products closely. Any drug-device combination (e.g. scaffold + therapeutic) typically requires demonstrating both device safety and drug safety, as well as the efficacy of the combined product, which is a high bar for approval. Gene therapy approaches face even greater regulatory hurdles due to the perceived risks of altering genetic material. However, encouragingly, some gene therapy for bone (like locally applied adenovirus-BMP2) have obtained compassionate use approvals in cases of life-threatening nonunions. Ethical aspects include ensuring that engineered tissues don't inadvertently cause harm (like tumorigenesis from implanted cells or unchecked bone overgrowth). Long-term follow-ups of patients who receive these advanced therapies will be crucial to establish safety profiles.

In summary, preclinical studies overwhelmingly support the benefit of integrating drug delivery with bone tissue engineering, demonstrating faster and more reliable bone regeneration across multiple models. Clinical translation is underway, with a few products already in practice and others in trials. For instance, a Phase I/II trial is evaluating a scaffold that releases BMP-2 and holds MSCs for regeneration of large mandibular defects after tumor resection. Preliminary results are promising, showing the formation of patient-specific live bone that restores jaw function. These real-world tests will continue to inform and refine the technology, bringing the most successful strategies (e.g. dual-factor release, gene-activated scaffolds) into standard orthopedic and reconstructive practice in the coming years.

Table 2. Summary of preclinical vs. clinical studies on drug-loaded scaffolds

Study Type	Scaffold/Delivery System	Drug/Growth Factor	Model/Patient Population	Key Outcomes	References
Preclinical (Rodents)	PLGA scaffold + alginate beads	BMP-2	Mouse femoral defect	Complete bridging, biomechanical strength restored	[24]
Preclinical (Rabbits)	Porous scaffold (dual delivery)	VEGF + BMP-2	Rabbit segmental defect	Enhanced vascularization and mature bone vs. BMP alone	[30]
Preclinical (Sheep)	3D-printed Ti scaffold + collagen hydrogel	BMP-2	Sheep tibial defect (30 mm)	Bridged defect, load-bearing healing in 3 months	[34]
Clinical (Spinal fusion)	Collagen sponge	rhBMP-2 (INFUSE™)	Thousands of patients	Higher fusion rates, but risk of ectopic bone, inflammation	[26]
Clinical (Non-union fractures)	Collagen putty	rhBMP-7 (OP-1)	Long-bone nonunions	Good healing in recalcitrant cases; limited adoption	[26][29]
Clinical (Craniofacial/Dental)	β-TCP matrix	PDGF (GEM 21S)	Periodontal defects	Significant bone fill and attachment gain	[29]
Pilot Human Trial	HA/TCP scaffold + MSCs (ex vivo)	Endogenous factors	Radius defect (Quarto et al.)	Bridging cortical bone regeneration	[24]

V. CHALLENGES AND LIMITATIONS

Despite the advancements discussed, several challenges must be addressed before drug-delivering tissue-engineered bone constructs achieve widespread clinical adoption:

Biocompatibility and Safety: All components of the delivery system the scaffold material, the encapsulated drug, any nanoparticles or viral vectors must be biocompatible and not elicit adverse reactions. Some delivery vehicles (e.g. certain cationic polymers for gene delivery, or high concentrations of metal nanoparticles) can be cytotoxic or pro-inflammatory. Ensuring that degradation products (such as acidic byproducts from PLGA or fragments of viral vectors) do not harm surrounding tissues is essential. Immune responses pose a particular challenge: for instance, an adenoviral vector delivering BMP-2 might cause a local immune/inflammatory reaction that counteracts bone formation or causes excess swelling. Strategies to mitigate this include using more biocompatible polymers, low-immunogenic or non-viral gene delivery methods, and careful dose optimization of both the carrier and the cargo【35】. Additionally, the long-term fate of delivery system components is important for example, if a scaffold does not fully degrade or remodel, it might act as a stress riser or harbor bacteria. Materials must degrade at a rate matched to new bone formation and ideally be replaced by natural bone. Any inorganic remnants (like residual bioceramic particles or metal nanoparticles) should not accumulate to a level that causes chronic issues.

Control of Release Kinetics: Achieving the desired release profile in vivo is notoriously difficult. In the complex environment of a healing bone defect, many factors (enzymes, local acidity, fluid flow, etc.) can alter how a delivery system performs compared to in vitro expectations. An initial burst that is too high might cause side effects (e.g. BMP-2 burst causing transient bone resorption or inflammation), whereas release that is too slow or too low may fail to induce healing. Stability of bioactive agents during processing and release is also a concern – proteins can denature during scaffold fabrication or lose activity if released too slowly. There is a need for improved modeling and monitoring of release in vivo. One interesting development is the use of imaging techniques (e.g. labeling growth factors with tracers)

to monitor their release and distribution after implantation, which can inform refinements in design. Nonetheless, lot-to-lot variability in materials and patient-to-patient differences in physiology mean that even approved systems like INFUSE have variable outcomes. Overcoming this variability might require adaptive delivery systems that adjust release in response to feedback, which is an area of ongoing research.

Manufacturing and Scale-Up: Producing combined scaffold-drug products is more complex than manufacturing an implant or a pharmaceutical alone. Reproducibility of drug loading and distribution within scaffolds at large scale can be challenging. For example, making thousands of porous scaffolds each loaded with exactly the same amount of BMP-2 and with identical release profiles is a tall order. Stringent quality control (QC) is required, including assays to confirm drug content and activity in each batch. Some scaffolds may need to be maintained in sterile conditions with drugs incorporated, which complicates packaging and shelf-life. Many biologics (proteins, genes) have limited stability, so the final product might need cold storage and have an expiration date. Lyophilization (freeze-drying) is sometimes used to improve shelf stability of drug-loaded matrices, but not all materials handle lyophilization well (e.g. it can cause pore collapse or burst releases). Regulatory agencies often classify these as combination products requiring coordination between device and drug regulations, which can prolong development timelines. Only a few companies have the interdisciplinary manufacturing capabilities to handle this, which is why relatively few products (like BMP on collagen sponge) have reached market to date.

Cost and Logistics: The incorporation of expensive biologics or sophisticated manufacturing steps can drive up cost. Recombinant growth factors are expensive to produce, and high doses (like the 12–24 mg of BMP-2 used in some spine surgeries) can make treatment extremely costly. Gene therapies are likewise expensive. Reducing cost might involve using lower doses with controlled release (thus more bang for the buck per molecule) or finding small-molecule alternatives to pricey proteins. Logistics is another factor – some products might require two components to be mixed during surgery (e.g. surgeon adds liquid growth factor to a freeze-dried scaffold in the operating room). This introduces complexity and possible user error. Simpler off-the-shelf products that are ready to use are preferable from a hospital workflow perspective.

Regulatory Barriers: As mentioned, combination products face detailed regulatory scrutiny. Demonstrating safety of new biomaterials in the body requires extensive animal testing. For gene-based approaches, regulators will likely require long-term follow-ups to ensure no insertional mutagenesis or germline transmission of vectors, etc. Each added functionality (a second drug, a new smart feature) multiplies the testing requirements, because one must show not only that each component is safe on its own, but that their combination is safe. There can also be hesitation to approve products that complicate the surgeon's task or require novel surgical procedures. Clear benefits must be shown over the current standard of care to justify any added risks or efforts.

Clinical Trial Design: Bone regeneration outcomes can be variable and heavily influenced by patient factors (age, health, defect type). Designing trials to test tissue-engineered therapies is challenging – for example, ethical considerations might prevent having an untreated control group if a standard bone graft exists. Many early studies have small sample sizes or are single-arm case series. Larger randomized controlled trials are needed but are expensive and difficult, especially for personalized or hospital-fabricated products. The field has also suffered from some overly optimistic early reports that did not fully pan out in broader use (e.g. BMP-2 complications not seen in small trials became evident in wider clinical use). Thus, new interventions must overcome a degree of caution in the orthopedic community.

Ethical and Practical Issues: If stem cells or gene edits are part of the therapy, there are ethical considerations regarding consent and long-term genetic effects. For patient-derived cells, logistical issues like harvesting and expanding cells (and the time needed for that) can limit clinical practicality for instance, a patient might not be able to wait weeks for an autologous cell-engineered construct to be prepared. "Off-the-shelf" allogeneic cells can be immunogenic unless

immunomodulated. Moreover, surgeons are typically trained in surgical techniques and may not be as familiar with handling bioactive implants (e.g. ensuring a drug-loaded scaffold stays hydrated, or that it is placed correctly to avoid drug diffusion to unwanted sites). Training and protocol standardization become important when biologics are involved.

In summary, while the promise of drug delivery-enhanced bone tissue engineering is great, researchers and clinicians must contend with issues of ensuring safety (no tumors, no ectopic bone in critical structures, no severe immune reactions), achieving consistent manufacturing and effects, and demonstrating clear improved outcomes to justify cost and complexity. Many of these challenges are being actively addressed: for example, new biomaterials are being developed that degrade into neutral pH byproducts to avoid acid-induced inflammation; novel release systems aim to confine factors strictly within the scaffold to avoid leakage; and advanced computational modeling is helping to predict optimal dosing, reducing the trial-and-error needed in development【28】【32】. As experience and data from preclinical and clinical studies accumulate, these limitations are gradually being surmounted. The next section will look ahead at how the field may evolve to overcome current barriers and enhance translational success.

VI. FUTURE PERSPECTIVES

The future of drug delivery in bone tissue engineering is bright, with interdisciplinary innovations driving the field toward more effective and personalized therapies. Several promising directions are emerging:

Personalized and 3D Printed Constructs: The convergence of medical imaging, design software, and 3D printing allows patient-specific scaffolds to be manufactured with precision【25】. In the future, a patient with a large bone defect could receive a custom scaffold printed to exactly fit their defect geometry, including features like internal channels for vascularization. This scaffold would be pre-loaded with the optimal cocktail of drugs/growth factors tailored to the patient's needs. Personalized factors might be determined by precision medicine approaches – for instance, a genetic or biomarker analysis might reveal that a patient has impaired BMP signaling (due to a genetic variation), so their scaffold could be loaded with a higher BMP-2 dose or an alternative pathway activator. AI and machine learning will likely assist in these personalized designs, predicting which patients will respond best to which regenerative factors and at what doses【28】【32】. Hospitals may even house "bioprinting" units where such customized, drug-infused bone grafts are manufactured on-demand before or during surgery.

Integration of Immunomodulation: Bone regeneration is increasingly understood to be linked with the immune response (the concept of osteoimmunology). Future scaffolds will likely carry cues to modulate the immune environment to one that favors regeneration. This could mean delivering anti-inflammatory agents or specific cytokines to encourage a shift from a pro-inflammatory (M1) macrophage phenotype to a pro-healing (M2) phenotype in the early post-injury period【35】. By fine-tuning the immune response, one can potentially reduce fibrosis and improve the activity of osteogenic signals. We anticipate composite delivery systems that release an initial burst of immunomodulators followed by sustained osteogenic factors, effectively orchestrating the entire healing cascade in a staged manner, similar to how the body naturally would.

Gene Editing and Stem Cell Augmentation: CRISPR-based therapeutics may evolve to the point where gene-edited MSCs or gene-activated matrices become routine【29】. For example, a patient's MSCs could be harvested and edited (using CRISPR/Cas9 or CRISPR activation systems) to overexpress osteogenic factors or to knock-out negative regulators of bone formation, then seeded onto a scaffold and implanted. Such cells could act as "living factories" for growth factors at the defect site, obviating the need for external protein delivery. Alternatively, scaffolds embedded with gene delivery vectors (like CRISPR-loaded nanoparticles or modified mRNA) could transiently edit or reprogram endogenous cells that migrate into the scaffold. This approach might achieve a more physiological regeneration by turning the patient's own wound-healing cells into osteoinductive cells. Ensuring precision and safety of gene editing in vivo will be the key challenge here, but the rapid advancements in CRISPR specificity and delivery suggest this is a plausible future avenue.

Multi-Functional Smart Scaffolds: Future scaffolds will not only deliver drugs but also sense and adapt. We might see scaffolds with built-in sensors (biosensors) that can relay information about the local environment (such as pH, oxygen level, strain) to external monitoring devices, or even autonomously adjust release. For instance, a scaffold could be engineered to release more BMP-2 if it "senses" (perhaps through a mechanically triggered release mechanism) that the defect is not progressing (i.e., insufficient load transfer which could be picked up by strain-sensing elements in the scaffold). Another scenario is a scaffold that can be re-loaded post-implantation e.g., magnetic nanoparticles in the scaffold that can be heated to trigger additional release cycles when stimulated externally, meaning months after surgery a clinician could non-invasively "boost" the scaffold's factor release by applying a magnetic field or ultrasound as needed.

AI-Driven Optimization: Artificial intelligence could play a significant role in optimizing drug delivery strategies. In silico models and machine learning trained on large datasets of prior experiments could predict the optimal scaffold design and drug regimen for a given defect and patient profile【28】【32】. This could greatly accelerate development, as candidate designs can be simulated for drug release and mechanical performance before ever entering an animal trial. AI might also guide patient selection and personalized therapy for example, by analyzing medical images and laboratory data, an AI algorithm could stratify which patients will heal with a simple scaffold vs. who will need a high-tech scaffold with multi-factor delivery, thereby applying resources more efficiently.

Clinical Translation and Collaboration: On the clinical front, we expect to see more convergence of specialties orthopedic surgeons, material scientists, and pharmacologists working closely. The regulatory landscape may also evolve; as more combination products demonstrate safety, regulatory agencies might establish clearer guidelines that streamline the approval process for these complex products. Furthermore, the cost barrier may lower with technological improvements in biomanufacturing automated, high-throughput fabrication of drug-laden scaffolds might reduce unit costs. If off-the-shelf allogeneic cell sources (like universal donor MSC lines or immune modulating exosomes) become available, they could be incorporated into scaffolds to further enhance outcomes without patient-specific cell sourcing.

From Bench to Bedside: The translational pipeline for these advanced therapies will likely involve stepwise clinical trials tackling specific challenging indications first for example, critical-sized defects in trauma patients or nonunions where standard care fails. Success in these difficult cases will build confidence and justify the use of these technologies in more routine scenarios like spinal fusion or dental bone grafting. Over time, as manufacturing scales up and familiarity grows, drug-enhanced bone grafts could become the new standard of care, much like how growth factor-eluting stents transformed cardiology.

In conclusion, the integration of smart drug delivery with scaffold-based bone repair is paving the way for truly regenerative therapies. Future bone tissue engineering constructs are expected to be bioinspired, dynamic implants that guide the body through the healing process by providing the right signals at the right time. The roadmap includes perfecting controlled release, ensuring safety, and personalizing therapy, with strong interdisciplinary and computational support. With these developments, the vision of reliably restoring large bone defects to normal, functional bone – without secondary graft sites or repeated surgeries – is on the horizon. Each incremental advance in this field brings us closer to that goal, promising improved quality of life for patients with debilitating bone injuries or defects.

VII. CONCLUSION

Drug delivery strategies have become an indispensable component of cutting-edge bone tissue engineering. By marrying the osteoconductive framework of scaffolds with the osteoinductive power of delivered bioactive molecules, researchers have greatly improved the prospects for regenerating large or otherwise untreatable bone defects. This review has detailed how conventional systemic therapies fall short for localized bone repair, and how localized controlled-release systems are overcoming those limitations. A wide spectrum of approaches is available: from scaffold materials (natural, synthetic,

composite) that slowly release growth factors, to nanoparticles that target bone tissue or respond to stimuli, to hydrogels that can be injected and gel in situ, as well as gene delivery vehicles that turn cells into factories for growth factors. Preclinical successes such as dual delivery of growth factors leading to vascularized bone or gene-activated scaffolds healing critical defects underscore the potential of these therapies【30】【32】. Early clinical applications (e.g. BMP-2 sponge, PDGF grafts) provide proof-of-concept that growth factor delivery can markedly enhance bone healing in patients【26】【29】.

At the same time, it is clear that challenges remain. Ensuring safety (avoiding ectopic bone, inflammation, or toxicity), achieving precise control over complex release profiles, and navigating regulatory pathways are non-trivial issues that researchers continue to address. The field is rapidly evolving to meet these challenges with innovative solutions like smart responsive systems and AI-optimized designs. As these technologies mature, we anticipate seeing more personalized and effective bone regenerative therapies entering clinical practice. In the near future, a patient with a massive bone defect may receive a custom-fabricated scaffold loaded with a sequence of biological cues one that actively coordinates the healing process by recruiting the patient's cells, combating infection or inflammation, and guiding new bone formation.

In summary, the integration of advanced drug delivery systems with bone tissue engineering holds the key to unlocking fully functional bone regeneration for challenging clinical scenarios. The current state-of-the-art demonstrates markedly improved outcomes in preclinical models and early human use, giving hope that problems like critical-size defects, nonunions, and large skeletal reconstructions can be managed with regenerative solutions rather than purely surgical ones. Continued interdisciplinary research and carefully designed clinical trials will be critical to translate these promising approaches into routine clinical care. With sustained effort, drug-augmented bone tissue engineering has the potential to revolutionize orthopedic and craniofacial reconstructive surgery, improving healing times and success rates while reducing patient morbidity. The "smart" bone grafts of tomorrow bioactive, instructive, and patient-tailored are poised to become a reality in the coming decade, fulfilling the long-sought goal of reliably regrowing healthy bone where it is needed.

REFERENCES

[1] Campana V., Milano G., Pagano E., et al. Bone substitutes in orthopaedic surgery: from basic science to clinical practice. J. Mater. Sci. Mater. Med. 2014;25(10):2445–2461. DOI: 10.1007/s10856-014-5240-2.

[2] Laubach M., Whyte S., Chan HF, et al. Lost in translation: the lack of agreement between surgeons and scientists regarding biomaterials for bone defects. BMC Med. 2024;22:517. DOI: 10.1186/s12916-024-03734-z.

[3] Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma. 1989;3(3):192–5. PMID: 2809873.

[4] Langer R., Vacanti JP. Tissue engineering. Science. 1993;260(5110):920–6. DOI: 10.1126/science.8493529.

[5] Giannoudis PV., Einhorn TA., Marsh D. Fracture healing: The diamond concept. Injury. 2007;38 Suppl 4:S3–6. DOI: 10.1016/j.injury.2007.02.012.

[6] Einhorn TA., Gerstenfeld LC. Fracture healing: mechanisms and interventions. Nat. Rev. Rheumatol. 2015;11(1):45–54. DOI: 10.1038/nrrheum.2014.164.

[7] Khan SN., et al. The biology of bone grafting. J Am Acad Orthop Surg. 2005;13(1):77–86. PMID: 15712985.

[8] Dimitriou R., Jones E., McGonagle D., Giannoudis PV. Bone regeneration: current concepts and future directions. BMC Med. 2011;9:66. DOI: 10.1186/1741-7015-9-66.

[9] Newman MR., Benoit DSW. Local and targeted drug delivery for bone regeneration. Curr Opin Biotechnol. 2016;40:125–32. DOI: 10.1016/j.copbio.2016.02.029.

[10] Low SA., Kopeček J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev. 2012;64(12):1189–204. DOI: 10.1016/j.addr.2012.01.012.

[11] O'Brien FJ. Biomaterials & scaffolds for tissue engineering. Mater Today. 2011;14(3):88–95. DOI: 10.1016/S1369-7021(11)70058-X.

[12] Urist MR. Bone: formation by autoinduction. Science. 1965;150(3698):893–9. DOI: 10.1126/science.150.3698.893.

[13] Levengood SL., Zhang M. Chitosan-based scaffolds for bone tissue engineering. J Mater Chem B. 2014;2(21):3161–84. DOI: 10.1039/C4TB00027G.

[14] Kretlow JD., Park J., Freed LE., Pelled G., Gizmol E., et al. Incorporating drug delivery into scaffold design for regenerative medicine. Sci. Transl. Med. 2010;2(19):19ps17. DOI: 10.1126/scitranslmed.3000110.

[15] Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials. 2000;21(24):2529–43. DOI: 10.1016/S0142-9612(00)00121-6.

[16] Rezwan K., Chen QZ., Blaker JJ., Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(18):3413–31. DOI: 10.1016/j.biomaterials.2006.01.039.

[17] Ghosh S., Webster TJ. Metallic nanoscaffolds as osteogenic promoters: advances and challenges. Metals (Basel). 2021;11(9):1356. DOI: 10.3390/met11091356.

[18] Yang DH., et al. Gold nanoparticles as an innovative therapeutic cue in bone tissue engineering: prospects and future applications. Mater Today Bio. 2024;26:101016. DOI: 10.1016/j.mtbio.2024.101016.

[19] Ogay V., et al. Progress and prospects of polymer-based drug delivery systems for bone tissue regeneration. Polymers (Basel). 2020;12(12):2881. DOI: 10.3390/polym12122881.

[20] Crasto G., et al. Ultrasound-triggered release of BMP-2 from liposomes within a fibrin scaffold for bone regeneration. Int J Nanomedicine. 2021;16:2515–2530. DOI: 10.2147/IJN.S299595.

[21] Liu M., Zeng X., Ma C., et al. Injectable hydrogels for cartilage and bone tissue engineering. Bone Res. 2017;5:17014. DOI: 10.1038/boneres.2017.14.

[22] Xue B., Zhang C., et al. A novel controlled-release system for antibacterial enzyme lysostaphin delivery using hydroxyapatite/chitosan composite bone cement. PLoS One. 2014;9(12):e115304. DOI: 10.1371/journal.pone.0115304.

[23] Boerckel JD., Kolambkar YM., Dupont KM., et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials. 2011;32(22):5241–51. DOI: 10.1016/j.biomaterials.2011.03.063.

[24] Quarto R., et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med. 2001;344(5):385–6. DOI: 10.1056/NEJM200102013440516.

[25] Johnson CT., et al. Lysostaphin and BMP-2 co-delivery reduces S. aureus infection and regenerates critical-sized segmental bone defects. Sci Adv. 2019;5(5):eaaw1228. DOI: 10.1126/sciadv.aaw1228.

[26] Sallent I., et al. The few who made it: commercially and clinically successful innovative bone grafts. Front Bioeng Biotechnol. 2020;8:952. DOI: 10.3389/fbioe.2020.00952.

[27] Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840–2. DOI: 10.1038/453840a.

[28] Wang Y., Wu Y., Ding X., et al. Harnessing the power of machine learning into tissue engineering: current progress and future prospects. Regen Biomater. 2024 (in press). DOI: 10.1093/rb/rbad086.

[29] Zhang TT., Wang W., Zhang Z., et al. "Genetic scissors" CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair. Bioact Mater. 2023;20:470–490. DOI: 10.1016/j.bioactmat.2022.09.023.

[30] Devi VKA., et al. Dual drug delivery platforms for bone tissue engineering. Front Bioeng Biotechnol. 2022;10:969843. DOI: 10.3389/fbioe.2022.969843.

[31] Lieberman JR., et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am. 1999;81(7):905–17. DOI: 10.2106/00004623-199907000-00001.

[32] Pobloth AM., et al. Mechanobiologically optimized 3D titanium-mesh scaffolds enhance bone regeneration in critical segmental defects in sheep. Sci Transl Med. 2018;10(423):eaam8828. DOI: 10.1126/scitranslmed.aam8828.

[33] Schlundt C., et al. Macrophages in bone fracture healing: their essential role in endochondral

ossification. Bone. 2015;106:78–89. DOI: 10.1016/j.bone.2015.10.019.

[34] Murphy CM., Haugh MG., O'Brien FJ. The effect of mean pore size on cell attachment, proliferation and migration in collagen–glycosaminoglycan scaffolds for bone tissue engineering. Biomaterials. 2010;31(3):461–466. DOI: 10.1016/j.biomaterials.2009.09.063.

[35] Mountziaris PM., Mikos AG. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng B Rev. 2008;14(2):179–86. DOI: 10.1089/ten.teb.2008.0038.